Novacyt (ALNOV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Novacyt (ALNOV) has a cash flow conversion efficiency ratio of -0.141x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.28 Million ≈ $-3.84 Million USD) by net assets (€23.34 Million ≈ $27.29 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Novacyt balance sheet independence to measure how much of total assets are equity-financed.
Novacyt - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Novacyt's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Novacyt cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Novacyt Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novacyt ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SIMPPLE LTD. Ordinary Shares
NASDAQ:SPPL
|
0.712x |
|
Loop Industries Inc
NASDAQ:LOOP
|
0.286x |
|
OpenSys M Bhd
KLSE:0040
|
-0.145x |
|
Metalstech Ltd
AU:MTC
|
-0.074x |
|
LOOP INDUSTRIES DL-001
F:3L9
|
0.241x |
|
Koss Corporation
NASDAQ:KOSS
|
-0.020x |
|
Lien Chang Electronic Enterprise Co Ltd
TW:2431
|
-0.008x |
|
Jinli Group Holdings Ltd
TW:8429
|
0.000x |
Annual Cash Flow Conversion Efficiency for Novacyt (2010–2025)
The table below shows the annual cash flow conversion efficiency of Novacyt from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Novacyt worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €23.34 Million ≈ $27.29 Million |
€-8.76 Million ≈ $-10.24 Million |
-0.375x | -82.93% |
| 2024-12-31 | €47.88 Million ≈ $55.98 Million |
€-9.82 Million ≈ $-11.48 Million |
-0.205x | +28.38% |
| 2023-12-31 | €87.24 Million ≈ $102.00 Million |
€-24.99 Million ≈ $-29.22 Million |
-0.286x | -140.40% |
| 2022-12-31 | €115.22 Million ≈ $134.70 Million |
€-13.73 Million ≈ $-16.05 Million |
-0.119x | -207.71% |
| 2021-12-31 | €141.81 Million ≈ $165.80 Million |
€15.69 Million ≈ $18.34 Million |
0.111x | -83.81% |
| 2020-12-31 | €150.71 Million ≈ $176.20 Million |
€102.98 Million ≈ $120.39 Million |
0.683x | +1029.33% |
| 2019-12-31 | €12.47 Million ≈ $14.58 Million |
€-916.70K ≈ $-1.07 Million |
-0.074x | -18.83% |
| 2018-12-31 | €18.15 Million ≈ $21.22 Million |
€-1.12 Million ≈ $-1.31 Million |
-0.062x | +66.82% |
| 2017-12-31 | €22.12 Million ≈ $25.86 Million |
€-4.12 Million ≈ $-4.82 Million |
-0.186x | -29.43% |
| 2016-12-31 | €15.15 Million ≈ $17.71 Million |
€-2.18 Million ≈ $-2.55 Million |
-0.144x | +71.63% |
| 2015-12-31 | €7.77 Million ≈ $9.08 Million |
€-3.95 Million ≈ $-4.61 Million |
-0.508x | -1099.81% |
| 2014-12-31 | €16.04 Million ≈ $18.75 Million |
€-678.92K ≈ $-793.73K |
-0.042x | +90.85% |
| 2013-12-31 | €1.94 Million ≈ $2.27 Million |
€-897.54K ≈ $-1.05 Million |
-0.462x | -236.32% |
| 2012-12-31 | €1.34 Million ≈ $1.57 Million |
€-184.36K ≈ $-215.54K |
-0.138x | -121.29% |
| 2011-12-31 | €-744.73K ≈ $-870.67K |
€-481.00K ≈ $-562.34K |
0.646x | +1707.09% |
| 2010-12-31 | €-846.00K ≈ $-989.06K |
€34.00K ≈ $39.75K |
-0.040x | -- |
About Novacyt
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive h… Read more